Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | FLT3 |
| Variant | D835E |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | FLT3 D835E lies within the activation loop in the protein kinase domain of the Flt3 protein (PMID: 25837374). D835E results in constitutive phosphorylation of Flt3 and activation of Stat5, Erk signaling, leading to transformation of cultured cells (PMID: 15256420). |
| Associated Drug Resistance | |
| Category Variants Paths |
FLT3 mutant FLT3 act mut FLT3 D835E FLT3 mutant FLT3 exon20 FLT3 D835X FLT3 D835E |
| Transcript | NM_004119.3 |
| gDNA | chr13:g.28018503A>C |
| cDNA | c.2505T>G |
| Protein | p.D835E |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_004119.3 | chr13:g.28018503A>C | c.2505T>G | p.D835E | RefSeq | GRCh38/hg38 |
| NM_004119.2 | chr13:g.28018503A>C | c.2505T>G | p.D835E | RefSeq | GRCh38/hg38 |
| NM_004119 | chr13:g.28018503A>C | c.2505T>G | p.D835E | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 D835E | acute myeloid leukemia | sensitive | Foretinib | Preclinical - Cell culture | Actionable | In a preclinical study, Foretinib (GSK1363089) inhibited viability of primary patient-derived acute myeloid leukemia blasts harboring FLT3 D835E in culture (PMID: 38231480). | 38231480 |
| FLT3 D835E | acute myeloid leukemia | sensitive | Gilteritinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xospata (gilteritinib) inhibited viability of primary patient-derived acute myeloid leukemia blasts harboring FLT3 D835E in culture (PMID: 38231480). | 38231480 |
| FLT3 D835E | acute myeloid leukemia | decreased response | Quizartinib | Preclinical - Cell culture | Actionable | In a preclinical study, primary patient-derived acute myeloid leukemia blasts harboring FLT3 D835E were less sensitive to Vanflyta (quizartinib) in culture (PMID: 38231480). | 38231480 |
| FLT3 D835E | hematologic cancer | sensitive | Gilteritinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 D835E in culture (PMID: 40196870). | 40196870 |
| FLT3 D835E | hematologic cancer | sensitive | Quizartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 D835E in culture (PMID: 40196870). | 40196870 |
| FLT3 D835E | hematologic cancer | sensitive | Midostaurin | Preclinical - Cell culture | Actionable | In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835E in culture (PMID: 40196870). | 40196870 |